| Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ... Annals of Oncology 30 (7), 1096-1103, 2019 | 559 | 2019 |
| Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers N Pozdeyev, LM Gay, ES Sokol, R Hartmaier, KE Deaver, S Davis, ... Clinical Cancer Research 24 (13), 3059-3068, 2018 | 446 | 2018 |
| Epithelial-to-mesenchymal transition activates PERK–eIF2α and sensitizes cells to endoplasmic reticulum stress Y Feng, ES Sokol, CA Del Vecchio, S Sanduja, JHL Claessen, TA Proia, ... Cancer discovery 4 (6), 702-715, 2014 | 293 | 2014 |
| Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence SJ Klempner, D Fabrizio, S Bane, M Reinhart, T Peoples, SM Ali, ... The oncologist 25 (1), e147-e159, 2020 | 279 | 2020 |
| Microsatellite-stable tumors with high mutational burden benefit from immunotherapy AM Goodman, ES Sokol, GM Frampton, SM Lippman, R Kurzrock Cancer immunology research 7 (10), 1570-1573, 2019 | 226 | 2019 |
| Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response M Montesion, K Murugesan, DX Jin, R Sharaf, N Sanchez, A Guria, ... Cancer Discovery 11 (2), 282-292, 2021 | 157 | 2021 |
| The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy TC Knepper, M Montesion, JS Russell, ES Sokol, GM Frampton, VA Miller, ... Clinical Cancer Research 25 (19), 5961-5971, 2019 | 142 | 2019 |
| Prospective comprehensive genomic profiling of primary and metastatic prostate tumors JH Chung, N Dewal, E Sokol, P Mathew, R Whitehead, SZ Millis, ... JCO precision oncology 3, 1-23, 2019 | 127 | 2019 |
| Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of … ES Sokol, D Pavlick, H Khiabanian, GM Frampton, JS Ross, JP Gregg, ... JCO precision oncology 4, 442-465, 2020 | 124 | 2020 |
| Growth of human breast tissues from patient cells in 3D hydrogel scaffolds ES Sokol, DH Miller, A Breggia, KC Spencer, LM Arendt, PB Gupta Breast Cancer Research 18, 1-13, 2016 | 123 | 2016 |
| Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1 YX Feng, DX Jin, ES Sokol, F Reinhardt, DH Miller, PB Gupta Nature communications 8 (1), 1079, 2017 | 120 | 2017 |
| Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations KB Pahuja, TT Nguyen, BS Jaiswal, K Prabhash, TM Thaker, K Senger, ... Cancer cell 34 (5), 792-806. e5, 2018 | 114 | 2018 |
| Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population CB Westphalen, MG Krebs, C Le Tourneau, ES Sokol, SL Maund, ... NPJ Precision Oncology 5 (1), 69, 2021 | 108 | 2021 |
| De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling CA Del Vecchio, Y Feng, ES Sokol, EJ Tillman, S Sanduja, F Reinhardt, ... PLoS biology 12 (9), e1001945, 2014 | 108 | 2014 |
| De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling CA Del Vecchio, Y Feng, ES Sokol, EJ Tillman, S Sanduja, F Reinhardt, ... PLoS biology 12 (9), e1001945, 2014 | 108 | 2014 |
| Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state Y Katz, F Li, NJ Lambert, ES Sokol, WL Tam, AW Cheng, EM Airoldi, ... Elife 3, e03915, 2014 | 100 | 2014 |
| Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project DM Vega, LM Yee, LM McShane, PM Williams, L Chen, T Vilimas, ... Annals of Oncology 32 (12), 1626-1636, 2021 | 96 | 2021 |
| Molecular determinants of response to PD-L1 blockade across tumor types R Banchereau, N Leng, O Zill, E Sokol, G Liu, D Pavlick, S Maund, LF Liu, ... Nature communications 12 (1), 3969, 2021 | 95 | 2021 |
| Homologous recombination deficiency: concepts, definitions, and assays MD Stewart, D Merino Vega, RC Arend, JF Baden, O Barbash, ... The oncologist 27 (3), 167-174, 2022 | 84 | 2022 |
| MHC-I genotype and tumor mutational burden predict response to immunotherapy AM Goodman, A Castro, RM Pyke, R Okamura, S Kato, P Riviere, ... Genome medicine 12, 1-13, 2020 | 82 | 2020 |
